Dr Natasha Leighl is the Lead Medical Oncologist at the Princess Margaret Hospital, OSI Pharmaceuticals Foundation Chair at the Princess Margaret Foundation, and a professor in the Department of Medicine at the University of Toronto, Canada.
Dr Leighl has a strong interest in researching the development of novel therapeutics in thoracic cancers and novel diagnostics for lung cancer. Dr Leighl has authored over 300 peer-reviewed papers, with many related to NSCLC. Her work covers multiple personalised therapy options targeting EGFR, ALK and MEK mutations, as well as immunotherapies. Her research also focuses on optimising biomarker testing and the need for comprehensive genomic profiling to treat NSCLC as the scope of targeted therapies continues to grow.
Dr Leighl is currently a member of the American Society of Clinical Oncology (ASCO) Thoracic Guidelines Advisory Group, the International Association for the Study of Lung Cancer (IASLC) Quality and Value Committee and serves on the Journal of Thoracic Oncology editorial board. Dr Leighl was also elected to the Americas Health Foundation Board of Directors and is a part of the Lung Cancer Foundation of America Scientific Advisory Board. She has also mentored multiple oncology trainees and was awarded the American Society of Clinical Oncology Excellence in Teaching Award in 2019.
EM-89207 - Date of preparation: February 2022